Ann Rheum Dis. Published Online First: 31 July 2006. doi:10.1136/ard.2006.052761
Review Article |
Experience with experimental biological treatment and local gene therapy of Sjögren's syndrome: implications for exocrine pathogenesis and treatment
1 NIH, AMC Amsterdam, United States
2 NIH, United States
3 AMC Amsterdam, Netherlands
* To whom correspondence should be addressed. E-mail: blodde{at}mail.nih.gov.
Accepted 22 July 2006
Abstract
Sjögrens syndrome (SS) is an autoimmune exocrinopathy, mainly affecting lacrimal and salivary glands and resulting in ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). The etiology and pathogenesis are largely unknown and only palliative treatment is currently available. Data obtained from experimental animal and human studies employing biological agents or gene therapeutics can offer insight into the SS disease process. Here, we review the current literature on these approaches and assess the lessons learned about the SS pathogenesis.
Keywords: Sjögren's syndrome, biological agents, exocrine gland, gene therapeutics, pathogenesis
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
